Almac Group
Almac Group, founded in 1968, is a global pharmaceutical company headquartered in Craigavon, County Armagh, GB, with a workforce of 7,500 employees and expertise in various pharmaceutical services.
Services
Almac Group provides a diverse range of services across the pharmaceuticals industry. Their specialities include API services and chemical development, formulation and analytical development, pharmaceutical development services, commercial manufacture, companion diagnostics, IRT & eCRA, clinical trial supply and management, diagnostics and biomarker discovery, and biostatistical consulting as part of their clinical technologies. They also offer comprehensive global clinical supply chain solutions, ensuring continuous delivery worldwide, and deliver clinical test services from their CLIA lab as part of their biomarker discovery and development efforts.
History
Founded in 1968, Almac Group has steadily grown its global presence and workforce, now operating 18 facilities worldwide, and headquartered in Craigavon, County Armagh, GB. With a team size of 4,367, Almac Group is a well-established entity in the pharmaceuticals industry. Noteworthy expansions include a £400 million development project that added two new facilities, and an £80 million expansion in Northern Ireland. These efforts have enabled them to contribute to over half of the approved NMEs in the last six years. Their growth trajectory continues with a significant record in revenue and strategic investments to enhance capabilities.
Global Locations
Almac Group has expanded its footprint globally, with significant operations in various locations. Their headquarters is in Craigavon, County Armagh, GB, while other notable locations include Tokyo, JP, Loughborough, Leicestershire, GB, Durham, NC, US, Souderton, PA, US, Lansdale, PA, US, Norristown, PA, US, Craigavon, Northern Ireland, GB, and Singapore, SG. Their global distribution allows them to deliver continuous and reliable services to clients and patients worldwide. The company has recently expanded its operations with the construction of a new facility in Montgomery County and enhanced cold chain facilities in Singapore.
Sustainability Initiatives
Almac Group is dedicated to sustainable practices and reducing its environmental impact. They signed a virtual power purchase agreement for renewable energy, which has significantly reduced global scope 2 emissions by 46%. Additionally, their headquarters in Northern Ireland benefits from a renewable energy agreement that has lowered carbon emissions from electricity consumption by 95%. These initiatives underline Almac Group's commitment to environmental responsibility and its efforts to promote sustainability within the pharmaceuticals industry.
Recent Achievements and Investments
Almac Group has made several key investments and achieved notable milestones in recent years. They expanded their Next Generation Sequencing capabilities with the addition of an Illumina NovaSeq™ X Plus instrument and grew their workforce by 150 employees in Durham, exceeding a total headcount of 500 in that location. They marked the groundbreaking of a $65 million facility expansion in Montgomery County, and have been awarded six 2024 CDMO Leadership Awards. Additionally, they supported the rapid launch of BioLineRx’s APHEXDA® (motixafortide) and nominated ALM-401 as a first-in-class bispecific next generation ADC targeting EGFR/ROR1.